Navigation Links
Essentialis Completes Patient Enrollment in Phase 2 Trial of DDCR for Treatment of Dyslipidemia
Date:11/23/2008

CARLSBAD, Calif., Nov. 23 /PRNewswire/ -- Essentialis Inc, a clinical stage pharmaceutical company, announced today that it has completed enrollment in a 92-patient Phase 2 trial of DCCR in dyslipidemic patients. The study encompasses both patients with very high triglycerides and mixed dyslipidemia and includes normal weight, overweight and obese patients presenting with or without hypertension.

The randomized, double-blind study is designed to assess the drug's effect on dyslipidemia and will evaluate three different doses of DCCR given over an 8-week period. Randomization was stratified by Body Mass Index (BMI) and concurrent use of statin drugs. The endpoints of the study include measurements of the effect of treatment on triglycerides, total-cholesterol, LDL-cholesterol, HDL-cholesterol and non-HDL-cholesterol, compared to placebo. The effects of DCCR on body weight, blood pressure and liver function tests compared to placebo are also being assessed. A total of 16 patients have completed the study, and an additional 20 have completed the double-blind treatment phase. The last patient last visit is scheduled for January 30th, 2009. Top-line results are anticipated in late March, 2009.

Commenting on this milestone achievement, Essentialis President and CEO, Iain Dukes said, "Essentialis is now closer to understanding the ability of DCCR to treat both very high triglycerides and mixed dyslipidemia, delivering a competitive profile of across the board lipid improvements with the added potential benefit of weight loss."

About DCCR

DCCR, diazoxide choline controlled release, is an ATP-dependent potassium channel agonist with potential utility in several cardiovascular and metabolic diseases. Extensive Phase 1 testing and investigator-sponsored clinical studies have demonstrated the drug's potential to lower triglycerides, non-HDL cholesterol and LDL-cholesterol while raising HDL-cholest
'/>"/>

SOURCE Essentialis Inc
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Vical Completes Enrollment and Reports Positive Interim Data in CMV Vaccine Phase 2 Trial
2. ViroPharma Incorporated Completes Acquisition of Lev Pharmaceuticals
3. Jennerex Completes the Treatment of First Patient Cohort in Phase 1 Trial With Intravenous Delivery of JX-594 Oncolytic Virus
4. Regado Biosciences Completes Patient Enrollment for Phase IIa Study of REG1 Anticoagulation System
5. Boston Scientific Completes Clinical Trial Enrollment for Third-Generation Drug-Eluting Stent
6. Peregrine Pharmaceuticals Completes Patient Enrollment in First Stage of Its Second Bavituximab Phase II Breast Cancer Trial
7. VIA Pharmaceuticals Completes Patient Visits in Phase 2 Acute Coronary Syndrome (ACS) Trial
8. Anthera Completes Special Protocol Assessment With FDA and Receives EMEA Scientific Advice on Development Path Toward Varespladib Approval
9. Arpida Completes Enrolment in Phase II "Intravenous-to-Oral" Switch Trial With Oral Iclaprim
10. Merck Serono Completes Enrollment in the REFLEX Trial of Rebif(R) in Patients at Risk of Developing Multiple Sclerosis
11. CuraGen Completes Enrollment in Phase II Trial of CR011-vcMMAE in Metastatic Melanoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2015)... 21, 2015  IntelliQuit™, the world,s first smartphone breathalyzer for smokers, was selected to present as ... New York City on Wednesday April 22.  ... ... ... Thirty percent (30%) of all cardiovascular disease is caused ...
(Date:4/21/2015)... ST. LOUIS , April 21, 2015 ... as a 5.4 percent decrease in utilization helped offset ... according to new data released today by Express Scripts ... Express Scripts Workers, Compensation Drug Trend Report discusses the ... opioid use among injured workers. Opioid ...
(Date:4/21/2015)... April 21, 2015  Navitas has launched Aviator, a ... range of offerings for life sciences clients. Aviator supports ... platform enabling seamless flow of data across all applications ... launch, Navitas worked closely with Oracle to provide Argus, ... CTMS in the Cloud. ...
Breaking Medicine Technology:IntelliQuit World's First Smartphone Breathalyzer for Smokers to Present to American Heart Association Innovation Investment Forum 2IntelliQuit World's First Smartphone Breathalyzer for Smokers to Present to American Heart Association Innovation Investment Forum 3Workers' Compensation Prescription Drug Spend Increased 1.9 Percent in 2014, Stabilized by Effective Utilization Management Programs 2Workers' Compensation Prescription Drug Spend Increased 1.9 Percent in 2014, Stabilized by Effective Utilization Management Programs 3Workers' Compensation Prescription Drug Spend Increased 1.9 Percent in 2014, Stabilized by Effective Utilization Management Programs 4Navitas Launches Aviator - Cloud Based Platforms for Oracle Solutions 2Navitas Launches Aviator - Cloud Based Platforms for Oracle Solutions 3Navitas Launches Aviator - Cloud Based Platforms for Oracle Solutions 4
... June 21 Gentris Corporation ( www.gentris.com ), ... that Rick Williams has joined the organization ... Board of Directors.  In his role as CEO of ... continues to provide biotechnology and pharmaceutical sponsors with the ...
... 21 Thomson Reuters announced today that it has launched ... the way biotechnology, pharmaceutical and academic organizations find partnering opportunities around ... , ... with drugs in development. It enables authorized users to share essential ...
Cached Medicine Technology:Gentris Corporation Names New Chief Executive Officer 2Gentris Corporation Names New Chief Executive Officer 3Gentris Corporation Names New Chief Executive Officer 4Thomson Reuters Creates The Outpartnering Registry, a Free Resource to Improve Drug Development Partnering 2Thomson Reuters Creates The Outpartnering Registry, a Free Resource to Improve Drug Development Partnering 3
(Date:4/21/2015)... Carinsurancehints.com has released a new blog post presenting ... auto insurance prices . , Commuting on ... should review their insurance options before deciding what plan ... forms. Some of the popular policies provide liability, collision ... rates and find the best prices in their area ...
(Date:4/21/2015)... 21, 2015 Edward Avalos, USDA Under ... Kawamura, former Secretary of the California Department of Food ... the 2nd Annual GrowRIVERSIDE Conference: The Future of Local ... inclusion of these nationally known experts intensifies an already ... farmers and others slated to speak at the June ...
(Date:4/21/2015)... CA (PRWEB) April 21, 2015 Respected ... PACS® strategy , Visage Imaging Inc. (“Visage”), ... PME), has signed a seven-year contract with University ... in Northern Florida. The deal furthers the penetration ... hospital space, a key area of the North American ...
(Date:4/21/2015)... 2015 Wojo Nutrition announces ... innovation at its healthiest, will carry Wojo Nutrition's lines ... At Wojo Nutrition, they’ve launched a revolution in the ... tailored to meet their multifaceted goals. Their line of ... any beverage, has been specially formulated to be as ...
(Date:4/21/2015)... Now in its fifteenth year, the TU-Automotive Detroit ... 3,000 senior attendees from across the automotive, technology ... on June 3 and 4. This year leading ... are set to deliver headline and keynote presentations ... as connectivity paves the way towards smart mobility ...
Breaking Medicine News(10 mins):Health News:Heavily Circulated Roads Can increase Auto Insurance Costs 2Health News:USDA Under Secretary, former CA Agriculture Director to Address 2nd Annual “GrowRIVERSIDE” Conference in June 2Health News:USDA Under Secretary, former CA Agriculture Director to Address 2nd Annual “GrowRIVERSIDE” Conference in June 3Health News:Visage Imaging Signs University of Florida Health 2Health News:Visage Imaging Signs University of Florida Health 3Health News:Visage Imaging Signs University of Florida Health 4Health News:Wojo Nutrition Announces their Lines of Single Serving Liquid Vitamins will be Available for Purchase online at Abesmarket.com Beginning in May 2Health News:TU-Automotive Detroit 2015 Sample Attendee List Released 2Health News:TU-Automotive Detroit 2015 Sample Attendee List Released 3
... the $50 million “YES Medical Technology Fund”, a ... companies with revenues and profits to expand their ... will provide growth capital to medtech companies that ... profitable (minimum $2 million EBITDA), and have the ...
... Unilens Vision Inc. (OTC,Bulletin Board: UVICF; TSX Venture Exchange: ... lenses, today reported,its operating results for the first quarter ... Net sales, excluding royalty income, increased ... in the previous year first,quarter (FY2008). The increase ...
... NEW YORK, Nov. 21 Keryx Biopharmaceuticals, Inc. (Nasdaq: ... 17, 2008, it received notice from The Nasdaq Stock ... in compliance with Marketplace Rule 4310(c)(3), which requires the ... equity, or $35,000,000 market value of listed securities, or ...
... DETROIT, Nov. 21 Caraco Pharmaceutical,Laboratories, Ltd. (NYSE Alternext US: ... the FDA warning letter on November 24, 2008 as planned.,In ... requested a,response from Caraco within 15 business days, ending November ... previously disclosed, the warning letter was issued as a follow ...
... VTAL ), a leading provider of advanced visualization ... agreed to,renew their global distribution agreement for five years, ... As under the previous agreement, Toshiba will offer ... than 50 nations in North and,South America, Europe, the ...
... surgery but either couldn,t afford it or were afraid of undergoing ... cosmetic surgery with a nonsurgical facelift that,s extremely safe, minimally invasive, ... ask for? , ... Coral Gables, FL (PRWEB) November ...
Cached Medicine News:Health News: Yankee Equity Solution ("YES") Launches $50 Million Fund for Mass.-Based Medtech Companies 2Health News:Unilens Vision Reports Record First Quarter Revenue, Earnings and Royalty Income 2Health News:Unilens Vision Reports Record First Quarter Revenue, Earnings and Royalty Income 3Health News:Unilens Vision Reports Record First Quarter Revenue, Earnings and Royalty Income 4Health News:Keryx Biopharmaceuticals Receives Nasdaq Notification 2Health News:Keryx Biopharmaceuticals Receives Nasdaq Notification 3Health News:Caraco Pharmaceutical Laboratories, Ltd. Update on FDA Warning Letter 2Health News:Vital Images and Toshiba Renew Distribution Agreement 2Health News:Vital Images and Toshiba Renew Distribution Agreement 3Health News:Miami's Soluna MD Introduces New Cosmetic Surgery Facelift Technique With Permalift 2Health News:Miami's Soluna MD Introduces New Cosmetic Surgery Facelift Technique With Permalift 3Health News:Miami's Soluna MD Introduces New Cosmetic Surgery Facelift Technique With Permalift 4
... The Fundus 20mm is a ... Lens. The Fundus 20mm provides ... increased 20mm contact element. The ... the contact element sits under ...
... The Volk Area Centralis® is excellent ... neovascularization and changes from macular degeneration, ... proliferative diabetic retinopathy and other retinal ... laser treatment of these conditions providing ...
... delivers the widest field of view ... .5x image magnification provides simultaneous visualization of ... providing a greater margin of safety during ... the ideal lens for visualization and treatment ...
... it the "Super 90". Volk's SuperField® has ... diagnosis for today's discriminating practitioner. Its ideal ... make it perfect as the primary high ... SuperField has been specifically designed for increased ...
Medicine Products: